CD163 and Miyoshi myopathy: Furthermore, in newly diagnosed (n = 5) and relapsed (n = 4) MM patients’ follow-up samples, after 2–3 months of treatment, no significant changes in CD163+EV and CD206+EV levels were observed compared to prior to treatment, while Ecto-CD163 and total sCD163 levels increased significantly during treatment [51].